Regulatory

FDA's 2025 Crackdown on Compounded GLP-1s: What It Means for Research Access

As the agency restores brand-name semaglutide and tirzepatide to its supply list, compounding pharmacies face new constraints — and researchers brace for downstream effects.

MC
Mara Costa
Senior Science Correspondent
Share

When the FDA quietly removed semaglutide and tirzepatide from its drug shortage list in early 2025, the ripple effects reached far beyond patients. Compounding pharmacies, which had built entire business lines around supplying lower-cost versions of these GLP-1 receptor agonists, were given a hard deadline to wind down operations under Section 503A of the Federal Food, Drug, and Cosmetic Act.

For researchers — academic, independent, and industry — the implications are subtler but no less significant.

"The shortage list was never meant to be a permanent business model — it was a temporary patch in a fragile supply chain."

A narrower supply pipeline

During the 2022–2024 shortage, compounded GLP-1s flowed into research environments through legitimate channels: institutional review board (IRB)–approved investigations, veterinary studies, and reference-standard procurement. With compounders restricted, those secondary supply lines have effectively closed.

"The shortage list was never meant to be a permanent business model — it was a temporary patch in a fragile supply chain," said Dr. Helena Mori, a regulatory affairs consultant who advises peptide manufacturers. "Now that the patch is being removed, anyone who relied on it is recalculating."

Research-use-only is not a loophole

A common misconception is that research-use-only (RUO) labeling exempts a substance from FDA oversight. It does not. RUO compounds remain subject to controlled-substance scheduling where applicable, customs regulations, and — critically — manufacturer claims liability. The FDA's 2025 guidance explicitly clarifies that RUO labeling does not authorize human administration, even in self-experimentation contexts.

For peptide suppliers operating under strict RUO frameworks, the post-shortage environment is paradoxically more stable. Demand has shifted toward suppliers with clear documentation, third-party COAs, and transparent batch tracing — exactly the operational rigor that survives regulatory scrutiny.

What comes next

The agency has signaled additional enforcement actions for 2026, with a focus on online marketplaces and cross-border shipments. Researchers should anticipate:

  • Longer customs hold times for international shipments
  • Greater scrutiny of bulk peptide purchases without institutional affiliation
  • Renewed attention to advertising claims, particularly those implying therapeutic benefit

The net effect is a tightening of the perimeter around legitimate research peptides — not a closure of it. Suppliers and end users who have always operated above the line will see relatively little change. Those who operated in the gray will find the gray has narrowed.

#FDA#GLP-1#Compounding#Regulatory
MC
Written by
Mara Costa
Senior Science Correspondent

Covers translational biology and regulatory affairs. Former STAT contributor.

Discussion

Verified researchers only

Comments are open to verified Protides community members.
Community verification is coming soon.

Talk to our ambassador
on WhatsApp